A reader noted that the Patent Office seems to be (undeservedly) dishing out more statutory double patenting rejections. Although the example dealt with claims directed to computer readable storage media and accompanying systems and methods, this can also be a problem in the bio/pharma where drug companies are constantly trying to file patent applications on continued changes and improvements in order to capture or retain market share.
Is the Patent Office dishing out more statutory double patenting rejections out of spite?
-
Yes, but they had it coming.
5%
-
Yes, but only until RCE's are banned.
20%
-
Yes, but only because they're bitter elitists.
45%
-
No, but they should.
15%
-
No, but how could it be worse?
15%
Created on Apr 23, 2008
Closed
Total Votes: 20
